Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer

• Status: Terminated
• Trial end date: 2008-06-25
• Target enrollment: 0
• Participant gender: All

Summary

The trial is conducted in Europe. This trial aims for a comparison of the pathology in lymph nodes before and after the effect of recombinant interleukin-21 in patients with stage III melanoma

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S

Criteria

Inclusion Criteria:

• Stage III melanoma

• ECOG performance status 0-1

Exclusion Criteria:

• Signs of stage IV melanoma

• Safety variables